Evidence map›Paper›PMID 37259259›Full record

ArticlePediatric blood & cancer2023

Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.

Kelly E Faulk, John A Kairalla, ZoAnn E Dreyer, Andrew J Carroll, Nyla A Heerema, Meenakshi Devidas, William L Carroll, Elizabeth A Raetz, Mignon L Loh, Stephen P Hunger and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 1 country.

Kelly E FaulkPediatric Oncology, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.ORCID https://orcid.org/0000-0002-8240-7490
John A KairallaBiostatistics, University of Florida, Gainesville, Florida, USA.
ZoAnn E DreyerPediatric Oncology, Texas Children's Hospital, Houston, Texas, USA.
Andrew J CarrollGenetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Nyla A HeeremaPathology, The Ohio State University, Columbus, Ohio, USA.
Meenakshi DevidasDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
William L CarrollDivision of Pediatric Hematology/Oncology, Perlmutter Cancer Center, and the New York University Grossman School of Medicine, New York, New York, USA.ORCID https://orcid.org/0000-0003-1550-4167
Elizabeth A RaetzDivision of Pediatric Hematology/Oncology, Perlmutter Cancer Center, and the New York University Grossman School of Medicine, New York, New York, USA.
Mignon L LohPediatric Oncology, University of Washington, Seattle, Washington, USA.
Stephen P HungerDivision of Oncology and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michael BorowitzPathology, Johns Hopkins University, Baltimore, Maryland, USA.
Cindy WangBiostatistics, University of Florida, Gainesville, Florida, USA.
Erin GuestDivision of Hematology, Oncology, Blood and Marrow Transplantation, Children's Mercy Kansas City, Kansas City, Missouri, USA.ORCID https://orcid.org/0000-0003-2482-5608
Patrick A BrownBristol Myers Squibb, Princeton, New Jersey, USA.
New York University · USUniversity of Florida Health · USBristol-Myers Squibb (United States) · USChildren's Hospital of Philadelphia · USChildren's Mercy Hospital · USJohns Hopkins University · USSt. Jude Children's Research Hospital · USTexas Children's Hospital · USThe Ohio State University · USUniversity of Alabama at Birmingham · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Washington · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5M
NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with KMT2A-germline acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study. For KMT2A-rearranged patients, 3-year event-free survival (EFS) by MRD-positive (≥0.01%) versus MRD-negative (<0.01%) was: TP1: 25% (±6%) versus 49% (±7%; p = .0009); TP2: 21% (±8%) versus 47% (±7%; p < .0001); and TP3: 22% (±14%) versus 51% (±6%; p = .0178). For KMT2A-germline patients, 3-year EFS was: TP1: 88% (±12%) versus 87% (±5%; p = .73); TP2: 100% versus 88% (±5%; p = .24); and TP3: 100% versus 87% (±5%; p = .53). MRD was a strong independent outcome predictor in KMT2A-rearranged, but not KMT2A-germline infant ALL.

Indexed as

acute lymphoblastic leukemiainfant leukemiaminimal residual disease

Identifiers

PMID37259259
PMCPMC10687300
OpenAlexW4378953208

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.